Distinguished in Multiple Myeloma

Lugui G. Qiu

Tianjin, CN 
Distinguished in Multiple Myeloma
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Lugui Qiu practices in Tianjin, China. Qiu is rated as a Distinguished expert by MediFind in the treatment of Multiple Myeloma. Their top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 306 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 128 articles and participated in 1 clinical trial in the study of Multiple Myeloma.

Locations

Tianjin, China
Other Locations
Beijing, China
Shanghai, 201615, China
Guangzhou, 510080, China
Hangzhou, China
Changsha, China
Nanchang, China
Jinan, China
Hubei Insect Resources Utilization And Sustainable Pest Management Key Laboratory, Wuhan, China
Hengshui, China
Xinxiang, China
300020, China
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 288 Nanjing Road, Xiaobailou, 300020, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I Study to Evaluate the Safety, Tolerability, PK/PD and Immunogenicity Characteristics of Recombinant Anti-CD38 and Anti-CD3 Bispecific Antibodies (Y150) for Injection in Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Study to Evaluate the Safety, Tolerability, PK/PD and Immunogenicity Characteristics of Recombinant Anti-CD38 and Anti-CD3 Bispecific Antibodies (Y150) for Injection in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Y150
Study Phase: Phase 1
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 26, 2022
Intervention Type: Biological
Study Drug: CD19 CAR T cells
Study Phase: Phase 1
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: March 17, 2020
Intervention Type: Biological
Study Drug: BZ019
Study Phase: Phase 1
View 5 Less Clinical Trials

306 Total Publications

Clinical characteristics and efficacy of short-course antibiotic therapy for Staphylococcus aureus bacteremia in hematological patients.
Clinical characteristics and efficacy of short-course antibiotic therapy for Staphylococcus aureus bacteremia in hematological patients.
Journal: Microbiology spectrum
Published: August 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qiu's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile